or Try an Advanced Search...

    Technical Analysis for BCAB - BioAtla, Inc.

    Grade Last Price % Change Price Change
    C 3.13 1.29% 0.04
    BCAB closed up 1.29 percent on Wednesday, May 8, 2024, on 87 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
    Earnings due: May 14
    *** please verify all earnings dates ***
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical BCAB trend table...
    Date Alert Name Type % Chg
    Shooting Star Candlestick Bearish 0.00%
    Calm After Storm Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.29%
    Calm After Storm Range Contraction 1.29%
    Wide Bands Range Expansion 1.29%
    Calm After Storm Range Contraction -1.26%
    Outside Day Range Expansion -1.26%
    Wide Bands Range Expansion -1.26%
    MACD Bullish Centerline Cross Bullish -3.69%
    Older End-of-Day Signals for BCAB ...

       Recent Intraday Alerts

    Alert Time
    Up 10% about 18 hours ago
    Non-ADX 1,2,3,4 Pullback Entry about 18 hours ago
    Rose Above Previous Day's High about 18 hours ago
    Up 5% about 18 hours ago
    60 Minute Opening Range Breakout about 20 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    BCAB Chart by TradingView
    Basic chart:

    Profile

    BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Clinical Medicine Drugs Health Care Tumor Cancer Immunotherapy Monoclonal Antibodies Non Small Cell Lung Cancer Melanoma Small Cell Lung Cancer Targeted Therapy Bladder Cancer Hepatocellular Carcinoma NSCLC Non Small Cell Lung Carcinoma Renal Cell Carcinoma Cervical Cancer Gastric Cancer

    Is BCAB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 8 BioAtla to Participate in the Citizens JMP Life Sciences Conference
    May 7 BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024
    May 6 BioAtla announces FDA clearance of ind application for its treatment of multiple tumors
    May 6 BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
    May 2 BioAtla: A Buried ADC Concern Gets Some New Life In 2024
    Apr 24 BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    Mar 28 We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully
    Mar 27 BioAtla, Inc. (NASDAQ:BCAB) Q4 2023 Earnings Call Transcript
    Mar 27 Q4 2023 Bioatla Inc Earnings Call
    Mar 26 BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript
    See more BCAB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.068
    52 Week Low 1.24
    Average Volume 652,938
    200-Day Moving Average 2.31
    50-Day Moving Average 2.86
    20-Day Moving Average 2.73
    10-Day Moving Average 2.88
    Average True Range 0.35
    RSI (14) 55.36
    ADX 22.29
    +DI 27.80
    -DI 18.79
    Chandelier Exit (Long, 3 ATRs) 2.81
    Chandelier Exit (Short, 3 ATRs) 3.07
    Upper Bollinger Bands 3.58
    Lower Bollinger Band 1.88
    Percent B (%b) 0.73
    BandWidth 62.53
    MACD Line 0.06
    MACD Signal Line -0.01
    MACD Histogram 0.077
    Fundamentals Value
    Market Cap 150.04 Million
    Num Shares 47.9 Million
    EPS -2.65
    Price-to-Earnings (P/E) Ratio -1.18
    Price-to-Sales 989.22
    Price-to-Book 1.47
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.75
    Resistance 3 (R3) 3.77 3.60 3.64
    Resistance 2 (R2) 3.60 3.44 3.58 3.61
    Resistance 1 (R1) 3.36 3.34 3.48 3.34 3.57
    Pivot Point 3.19 3.19 3.25 3.17 3.19
    Support 1 (S1) 2.95 3.03 3.07 2.93 2.69
    Support 2 (S2) 2.78 2.93 2.76 2.65
    Support 3 (S3) 2.54 2.78 2.62
    Support 4 (S4) 2.52